Wed, May 23, 2018
Tue, May 22, 2018
Mon, May 21, 2018
Fri, May 18, 2018
Thu, May 17, 2018
Wed, May 16, 2018
Tue, May 15, 2018
Mon, May 14, 2018
Fri, May 11, 2018
Thu, May 10, 2018
Wed, May 9, 2018
Tue, May 8, 2018
Mon, May 7, 2018
Fri, May 4, 2018
Thu, May 3, 2018
Wed, May 2, 2018
Tue, May 1, 2018

David Lebovitz Maintained (ALNY) at Hold with Decreased Target to $107 on, May 7th, 2018


//stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-107-on-may-7th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $118 to $107 on, May 7th, 2018.

David has made no other calls on ALNY in the last 4 months.



There are 4 other peers that have a rating on ALNY. Out of the 4 peers that are also analyzing ALNY, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Stephen Willey of "Stifel" Maintained at Hold with Decreased Target to $95 on, Friday, May 4th, 2018
  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $135 on, Thursday, January 25th, 2018


These are the ratings of the 2 analyists that currently disagree with David


  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $134 on, Friday, May 4th, 2018
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $154 on, Tuesday, March 13th, 2018

Publication Contributing Sources